Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial
Practical Solutions and Value
Nonalcoholic fatty liver disease (NAFLD) is closely linked to type 2 diabetes mellitus (T2DM). This clinical trial aims to compare the effectiveness and safety of combining semaglutide and empagliflozin for patients with NAFLD and T2DM.
The study involves 105 overweight/obese subjects with NAFLD and T2DM and will last for 52 weeks. Key outcomes will include changes in liver health markers, blood glucose, lipid levels, and other relevant factors. Interim and safety analyses will also be conducted.
This clinical trial explores the combined effects of semaglutide and empagliflozin and aims to provide important insights into their mechanisms in patients with NAFLD and T2DM.
Value of Clinical Trials
Clinical trials are crucial for developing safe and effective treatments, and it’s essential to integrate their benefits into everyday medical practice. DocSym, our AI-driven platform, consolidates clinical standards and research, offering a comprehensive knowledge base for clinicians.
In today’s healthcare landscape, optimizing operations is vital. Our mobile apps support scheduling, treatment monitoring, and telemedicine, simplifying patient care management and digital service expansion.
By leveraging AI, clinics can streamline workflows and enhance patient outcomes, reducing paperwork. Explore how we can support your practice at aidevmd.com.
